Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rana McKay

Hematology & Oncology San Diego, CA Medical Doctor

NPI 1306013610 CMS profile 541869

200 W Arbor Dr, San Diego, CA 92103

Open in the dashboard

General payments

$530,093

379 records reported · program years 2019–2025

Research payments

$18,041

Paid to them · 18 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$14,752,959 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Rana McKay of San Diego, CA is reported in the CMS Open Payments database as having received $530,093 across 379 general payments and $18,041 in research payments paid to them. Separately, studies naming them as principal investigator received $14,752,959 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $88,428 78
2025 Research $13,238 9
2024 General $140,620 75
2024 Research $3,353 4
2023 General $86,927 69
2022 General $66,951 56
2022 Research $1,449 5
2021 General $70,069 39
2020 General $53,890 32
2019 General $23,208 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rana McKay
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Rana McKay were reported at $88,428. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Rana McKay Hematology & Oncology median Middle half National median
2019 $23,208 $529 $121–$2,516 $163
2020 $53,890 $339 $82–$2,213 $114
2021 $70,069 $263 $49–$1,965 $132
2022 $66,951 $416 $103–$2,395 $149
2023 $86,927 $542 $125–$2,646 $160
2024 $140,620 $692 $141–$3,008 $164
2025 $88,428 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $121,625 53 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $65,398 54 payments
  3. Pfizer Inc. $55,691 33 payments
  4. Exelixis Inc. $50,703 63 payments
  5. AstraZeneca UK Limited $41,895 17 payments
  6. E.R. Squibb & Sons, L.L.C. $31,173 36 payments
  7. Novartis Pharmaceuticals Corporation $26,458 15 payments
  8. Daiichi Sankyo Inc. $18,230 12 payments
  9. Genzyme Corporation $17,555 7 payments
  10. AstraZeneca Pharmaceuticals LP $15,072 20 payments
  11. Other $86,292 69 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $363,369 174 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $99,686 21 payments
  3. Honoraria $32,230 18 payments
  4. Travel and Lodging $28,053 33 payments
  5. Food and Beverage $6,561 123 payments
  6. Education $194 10 payments
Products named General payments · program years 2019–2025
  1. CABOMETYX $35,176 43 payments
  2. LYNPARZA $26,544 14 payments
  3. TALZENNA $23,177 11 payments
  4. JEVTANA $15,392 6 payments
  5. XTANDI $14,701 4 payments
  6. ORGOVYX $13,600 3 payments
  7. PLUVICTO $13,173 9 payments
  8. PROVENGE $12,554 11 payments
  9. ERLEADA $10,808 7 payments
  10. FOTIVDA $10,561 9 payments
  11. Other $75,137 94 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Pfizer Inc. $11,890 10 payments
  2. Novartis Pharmaceuticals Corporation $4,701 3 payments
  3. Eli Lilly and Company $1,298 1 payment
  4. Aveo Pharmaceuticals, Inc. $151 4 payments

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

202

Median for Hematology-Oncology: 604

Drug cost

$735,640

Median for Hematology-Oncology: $1,306,514

Branded share of claims

34.7%

Median for Hematology-Oncology: 31.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cabometyx Cabozantinib S-Malate Brand 11 $314,995
Xtandi Enzalutamide Brand 18 $237,465
Abiraterone Acetate Generic 43 $100,442
Orgovyx Relugolix Brand 29 $75,078
Eliquis Apixaban Brand 12 $6,886
Prochlorperazine Maleate Generic 18 $390
Prednisone Generic 55 $275
Levothyroxine Sodium Generic 16 $108

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$70,097

Medicare's payments for the services billed

Medicare patients

225

Average age 74

Services billed

738

14 women, 211 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Cancer 75%
High blood pressure 70%
Arthritis 39%
Ischemic heart disease 36%
Chronic kidney disease 36%
Diabetes 25%
Osteoporosis 25%
Heart failure 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LYNPARZA
  • AstraZeneca UK Limited $7,535
  • AstraZeneca Pharmaceuticals LP $2,569
$10,104 — —
ORGOVYX
  • PFIZER INC. $5,500
$5,500 29 —
CABOMETYX
  • Exelixis Inc. $5,264
$5,264 11 —
PLUVICTO
  • Novartis Pharmaceuticals Corporation $2,400
$2,400 — —
FOTIVDA
  • Aveo Pharmaceuticals, Inc. $2,220
$2,220 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

397 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record